Breakthrough Treatment for Rare Eye Disease Shows Exceptional Results

Elegrobart Achieves 54-63% Response Rates for Thyroid Eye Disease

For patients suffering from thyroid eye disease — a rare but devastating condition that can cause vision problems and facial disfigurement — Viridian Therapeutics has announced breakthrough Phase 3 trial results that offer genuine hope for effective treatment.

The company's drug Elegrobart achieved response rates of 54% and 63% in its two Phase 3 trials, dramatically outperforming the 18% placebo response rate. Even more encouraging, 51% of patients experienced complete resolution of diplopia (double vision), one of the most debilitating symptoms of the condition.

Thyroid eye disease affects people with both overactive and underactive thyroid conditions, causing inflammation and swelling of the muscles and tissues around the eyes. This can lead to bulging eyes, double vision, difficulty closing the eyes, and in severe cases, vision loss. The psychological impact is equally significant, as changes in appearance can severely affect patients' quality of life and self-confidence.

Current treatment options are limited and often involve steroids with significant side effects, making Elegrobart's success particularly meaningful for this underserved patient population.

Key Facts

• Key Facts & Figures
  • 54% and 63% response rates in Phase 3 trials vs 18% placebo — Viridian Therapeutics
• 51% of patients achieved complete resolution of double vision
• Phase 3 trials included multiple endpoints measuring disease activity
• Thyroid eye disease affects estimated 16 people per 100,000 annually
• Current treatments largely limited to steroids with significant side effects